Norrin-Mediated Junction Tightening for Retinal Edema
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Retinal edema associated with compromised retinal vasculature leakage is not effectively addressed by existing treatments, as they fail to adequately restore inter-cellular junctions and reduce fluid accumulation in conditions like macular degeneration and FEVR.
Innovation Solution
Exposure of retinal or choroidal vessel cells to norrin protein to selectively up-regulate gene expression of VE-cadherin and claudin-5, tightening inter-cellular junctions and reducing leakage, which can be administered via intraocular, oral, or topical routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing treatments are applied to retinal edema, then fluid accumulation is addressed, but inter-cellular junction integrity is not restored
Solution Approach 1:
Norrin acts as a mediator protein that binds to Frizzled-4 receptors on retinal vascular endothelial cells, triggering intracellular signaling cascades that restore VE-cadherin and claudin-5 expression. This intermediary mechanism simultaneously addresses both fluid leakage and junctional integrity by activating pathways that upregulate adhesion molecules while reducing vascular permeability.
Solution Approach 2:
The treatment changes the expression levels of key junctional proteins (VE-cadherin and claudin-5) from depleted to restored states, and modifies the functional state of tight junctions from compromised to intact. Norrin administration induces parameter changes in gene expression, protein synthesis, and junctional assembly that collectively restore vascular barrier function and reduce edema.
2Productivity
If VEGF is up-regulated to compensate for ischemia, then oxygen and nutrient delivery is improved, but vessel permeability increases causing edema
Solution Approach 1:
The invention converts the harmful effect of VEGF-induced permeability into a beneficial outcome by using norrin to selectively restore junctional proteins in VEGF-upregulated vessels. The high VEGF environment, which normally causes leakage, becomes an opportunity for norrin-mediated junctional repair, where the same ischemic drive that increases permeability also creates the biological context for norrin to upregulate VE-cadherin and claudin-5 expression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces inter-cellular leakage and fluid accumulation in the retina, improving the integrity of Tight and Adherens Junctions, thereby treating retinal edema and related conditions such as macular degeneration and FEVR.
Implementation Method 1
Norrin is a ligand for the Frizzled receptor subtype 4 (Fz4). Norrin binds Fz4 with nanomolar affinity
Implementation Method 2
The inactivation of glycogen synthase kinase (GSK) 3β and Axin through frizzled receptor binding stabilizes β-catenin, which subsequently accumulates in the cell nucleus and activates the transduction of target genes
Implementation Method 3
Tight Junctions include transmembrane proteins, including occludin, claudin-5, and junctional adhesion molecules (JAMs)... These are shown schematically in prior art FIG. 1. While the transmembrane proteins mediate cell-cell adhesion
Data Source
AI summary
A method of tightening inter-cellular junctions in retinal or choroidal vessel cells includes exposing the retinal or choroidal vessel cells to norrin and an anti-VEGF agent. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 in the retinal or choroidal vessel cells, the inter-cellular junctions are tightened. The method is also suitable for treating retinal pigment epithelial cells in wet macular degeneration.